Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib
Saved in:
| Published in: | Research and Practice in Thrombosis and Haemostasis |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2022
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib
- Evaluation of muscle strength and renal function in survivors of severe COVID-19: A 12-month follow-up study
- How to use and report data on D‐dimer testing in the COVID‐19 era?
- Positive fluid balance is associated with earlier acute kidney injury in COVID-19 patients
- Pulmonary embolism–related mortality during the COVID‐19 pandemic: Data from the United States
- Uncertainties on the prognostic value of admission D‐dimer on venous thromboembolism occurrence in patients with COVID‐19
- Admission biomarkers and COVID-19 mortality: A retrospective study during Vietnam’s pandemic peak